This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Lung cancer	Epidermal growth factor receptor (EGFR)	<i>In vitro</i> and mouse studies identified 2,8-dianilino-purine compounds that could help treat EGFR-mutant lung cancer. <i>In vitro</i> , a lead compound inhibited EGFR with an IC ₅₀ value of 4 nM. In mice with human lung cancer cells, the compound decreased tumor growth compared with an equivalent dose of the EGFR inhibitor Iressa gefitinib. Next steps could include additional preclinical pharmacokinetic studies. AstraZeneca plc markets Iressa in the EU to treat non-small cell lung cancer (NSCLC).	Patent application filed; unavailable for licensing	Yang, S.-Y. <i>et al. J. Med. Chem.</i> ; published online Nov. 1, 2012; doi:10.1021/jm301365e Contact: Sheng-Yong Yang, Sichuan University, Sichuan, China e-mail: yangsy@scu.edu.cn
SciBX 5(45); doi:10.1038/scibx.2012.1180 Published online Nov. 15, 2012				